Finding and treating oral melanoma, squamous cell carcinoma, and fibrosarcoma in dogs - Veterinary Medicine
  • SEARCH:
Medicine Center
DVM Veterinary Medicine Featuring Information from:

ADVERTISEMENT

Finding and treating oral melanoma, squamous cell carcinoma, and fibrosarcoma in dogs
The three malignancies most likely to occur in dogs' mouths can have devastating local or metastatic effects if not identified and treated quickly. Review how surgery—in conjunction with radiation, chemotherapy, or vaccination—may increase your patients' survival times.


VETERINARY MEDICINE


45. LaDue-Miller T, Price GS, Page RL, et al. Radiotherapy of canine non-tonsillar squamous cell carcinoma. Vet Radiol Ultrasound 1996;37(1):74-77.

46. Rassnick KM, Ruslander DM, Cotter SM, et al. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). J Am Vet Med Assoc 2001;218(9):1444-1448.

47. Boria PA, Murry DJ, Bennett PF, et al. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 2004;224(3):388-394.

48. Knapp DW, Glickman NW, Widmer WR, et al. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 2000;46(3):221-226.

49. Schmidt BR, Glickman NW, DeNicola DB, et al. Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 2001;218(11):1783-1786.

50. de Vos JP, Burm AGD, Focker AP, et al. Piroxicam and carboplatin as a combination treatment of canine oral non-tonsillar squamous cell carcinoma: a pilot study and a literature review of a canine model of human head and neck squamous cell carcinoma. Vet Comp Oncol 2005;3(1):16-24.

51. Modiano JF, Ritt MG, Wojcieszyn J. The molecular basis of canine melanoma: pathogenesis and trends in diagnosis and therapy. J Vet Intern Med 1999;13(3):163-174.

52. Moore AS, Theilen GH, Newell AD, et al. Preclinical study of sequential tumor necrosis factor and interleukin 2 in the treatment of spontaneous canine neoplasms. Cancer Res 1991;51(1):233-238.

53. Alexander AN, Huelsmeyer MK, Mitzey A, et al. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Cancer Immunol Immunother 2006;55(4):433-442.

54. Bergman PJ, Camps-Palau MA, McKnight JA, et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006;24(21):4582-4585.

55. Bergman PJ, McKnight J, Novosad A, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003;9(4):1284-1290.


ADVERTISEMENT

Source: VETERINARY MEDICINE,
Click here